. The steps in Moco synthesis emerged from bacterial genetic analyses 3 . Human Moco deficiency causes seizures, progressive neurological damage, and neonatal death 4, 5 . Moco is an essential cofactor for four animal enzymes, sulfite oxidase, xanthine oxidase, aldehyde oxidase, and the mitochondrial amidoxime reducing component 4 , but loss of sulfite oxidase activity is suspected to be the primary pathology in human Moco deficiency 1 . As Moco is unstable, it has not been thought to be transferred between cells, tissues, or organisms.
Here we show that C. elegans can acquire mature Moco and a Moco precursor (cyclic pyranopterin monophosphate (cPMP)) from its bacterial diet. We show that there is arrested development in C. elegans lacking endogenous Moco synthesis and dietary Moco, due to an inability to detoxify sulfite. C. elegans cystathionine gammalyase and cysteine dioxygenase, conserved components of the sulfur amino acid catabolism pathway, generate sulfite that is lethal when Moco is deficient 6 . In the absence of sulfur amino acid catabolism, Moco is no longer necessary. Thus, interkingdom transport of Moco from microbes to C. elegans acts in sulfite detoxification.
Results
Moco synthesis and dietary acquisition in C. elegans. We explored the function of Moco and its biosynthetic enzymes in C. elegans. Genome sequence analysis using protein queries from E. coli Moco biosynthesis enzymes identified C. elegans homologs for each of the seven core Moco-biosynthesis proteins ( Fig. 1a and Supplementary Table 1) 1 . We characterized phenotypes of C. elegans with loss-offunction mutations in six predicted Moco biosynthesis enzymes; moc-1, moc-2, moc-3, moc-4 (T27A3.6), moc-5 (F49E2.1), and lin-46 (refs. [7] [8] [9] ). Surprisingly, given that Moco biosynthesis is essential in humans, C. elegans strains carrying mutations in any of these genes were viable and grew normally on wild-type E. coli. We reasoned that C. elegans acquires Moco from the E. coli, which is competent for Moco synthesis, on which it feeds. In the wild, C. elegans consumes many different species of bacteria in rotting fruit. As Moco biosynthesis is not universal to all bacteria, it is reasonable to expect C. elegans to import bacterial Moco as well as synthesize Moco de novo 10 . To test this hypothesis, we grew wild-type and Moco-biosynthesismutant C. elegans strains on an E. coli strain with a deletion in MoaA, the first step in Moco biosynthesis. This ΔMoaA E. coli strain, which grows at a normal rate on LB or nematode growth media (NGM), cannot synthesize Moco or any of the Moco precursor metabolites. Wild-type C. elegans grows normally when fed on ΔMoaA E. coli, demonstrating that microbial Moco biosynthesis is not required for the viability of wild-type C. elegans (Fig. 1b) . C. elegans with a mutation in moc-1, moc-2, moc-3, moc-4, or moc-5 had arrested development or died at early larval stages when grown on ΔMoaA E. coli, in contrast to C. elegans mutants fed with wild-type E. coli, which showed healthy growth (Figs. 1b, 2a-f). Of the six putative C. elegans Moco-biosynthesis mutants tested, only the lin-46 mutant grew normally on ΔMoaA E. coli ( Supplementary Fig. 1 ). LIN-46 and MOC-1 are paralogous, probably emerging from a MoeA duplication event. LIN-46 displays less sequence similarity to MoeA than MOC-1 (Supplementary Table 1) , and thus may be functionally divergent. Mutations in lin-46 emerged from studies of microRNA (miRNA) biology and were not characterized further here 7 . We also found evidence for maternal contribution of Moco: when moc-1, moc-2, moc-3, moc-4, and moc-5 mutant C. elegans mothers were fed ΔMoaA E. coli from the L4 stage of development, one stage prior to reproductive adulthood, progeny viability dropped dramatically (Supplementary Table 2 ). Embryo viability was not affected when wild-type mothers were fed wild-type or ΔMoaA E. coli. Thus, our data suggest that Moco is transferred from mother to progeny.
We identify redundant pathways for maintaining sufficient Moco in C. elegans: endogenous Moco biosynthesis and acquisition from dietary E. coli. To test whether the ability of E. coli to synthesize Moco and transfer it to C. elegans is common in bacterial species associated with C. elegans in the wild, we examined the growth of moc-1 mutant C. elegans cultured on six bacterial strains isolated from the natural Caenorhabditis microbiome 10, 11 . C. elegans moc-1 mutants grew and developed on all six natural bacterial isolates tested, representing five unique bacterial phyla (Fig. 1b and Supplementary Table 3) . Thus,
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The kingdoms of life share many small molecule cofactors and coenzymes. Molybdenum cofactor (Moco) is synthesized by many archaea, bacteria, and eukaryotes, and is essential for human development. The genome of Caenorhabditis elegans contains all of the Moco biosynthesis genes, and surprisingly these genes are not essential if the animals are fed a bacterial diet that synthesizes Moco. C. elegans lacking both endogenous Moco synthesis and dietary Moco from bacteria arrest development, demonstrating interkingdom Moco transfer. Our screen of Escherichia coli mutants identifies genes necessary for synthesis of bacterial Moco or transfer to C. elegans. Developmental arrest of Moco-deficient C. elegans is caused by loss of sulfite oxidase, a Moco-requiring enzyme, and is suppressed by mutations in either C. elegans cystathionine gamma-lyase or cysteine dioxygenase, blocking toxic sulfite production from cystathionine. Thus, we define the genetic pathways for an interkingdom dialogue focused on sulfur homeostasis. diverse bacterial species from the natural Caenorhabditis habitat supply Moco to C. elegans, suggesting that this is a conserved and robust host-microbe interaction. C. elegans may retain its Moco biosynthetic genes because not all bacterial species that it naturally consumes synthesize Moco. Genome analyses showed that 325 out of 451 bacterial species carry Moco biosynthesis genes 2 . In eukaryotes, Moco biosynthetic genes are generally present, but particular fungal and protist species lack Moco biosynthesis. C. elegans acquires microbial cPMP and Moco. To define the comprehensive set of E. coli gene activities that are required for the synthesis or transfer of Moco to C. elegans, we tested the growth of the moc-1 mutant animals on each of the approximately 4,000 mutant strains of the Keio E. coli deletion mutation collection 12 . We screened for E. coli mutant strains that permit growth of wild-type C. elegans, but not moc-1 mutant animals. This screen identified 12 E. coli genes that are specifically required for the viability of moc-1 mutant animals ( Supplementary Fig. 2a ). The genes identified include the seven enzymes that synthesize Moco from GTP (MoaA, MoaC, MoaD, MoaE, MoeA, MoeB, and MogA). We also identified the E. coli ABC-type transport system for acquisition of environmental molybdenum for incorporation into Moco (ModA, ModB, and ModC) 13 . Finally, we discovered two new E. coli genes that have no known function in Moco biosynthesis, YdaV and YehP.
Ten of the 12 E. coli mutations that disrupt the growth of moc-1 mutant C. elegans disrupt steps in Moco biosynthesis. These data strongly suggest that Moco or biochemical precursors in the E. coli Moco biosynthetic pathway are acquired and used by C. elegans. We used a matrix of E. coli and C. elegans Moco biosynthetic mutant combinations to determine which molecules are transferred from E. coli to C. elegans. Keio collection kanamycin-resistant insertion and deletion mutations are likely to be polar, downregulating the expression of downstream genes in the operon and precluding disruption of single biochemical steps in Moco synthesis ( Supplementary Fig. 2b,c) . To precisely analyze E. coli single gene disruptions, the mutations were rendered nonpolar via Flp recombinase-mediated removal of each kanamycin cassette 14 . Of the 12 E. coli mutant strains identified in our screen, we generated nonpolar versions of all but the ModB mutation. Of the 11 nonpolar mutant strains generated, all but YehP recapitulated the larval lethality of moc-1 mutant C. elegans, consistent with the original polar Keio E. coli mutations. This result suggests that the downstream 
Animal length (µm) n = 10 individuals per data point gene in the Yeh operon, YehQ, may also need to be inactive for E. coli to fail in Moco biosynthesis or transport ( Supplementary Fig. 3a,b) . We did not further analyze this operon. The 10 other nonpolar E. coli mutations were further analyzed for their ability to support the growth and development of C. elegans mutants that harbour defects at defined points in Moco biosynthesis.
We challenged wild-type, moc-1, moc-2, moc-3, moc-4, or moc-5 mutant C. elegans to grow on wild-type E. coli, or E. coli with nonpolar mutations in MoaA, MoaC, MoaD, MoaE, MoeA, MoeB, MogA, ModA, ModC, or YdaV ( Fig. 2 and Supplementary Fig. 3c-h ). C. elegans moc-1, moc-2, moc-3, and moc-4 mutant animals were viable only on wild-type E. coli able to synthesize mature Moco (Fig. 2) . This suggests that C. elegans acquire Moco from their diet: moc-1 mutant animals cannot use other Moco-precursors from bacteria to synthesize mature Moco, and the growth of moc-2, moc-3, and moc-4 mutants is not rescued when their respective downstream Moco-metabolites (molybdopterin (MPT), adenylated molybdopterin (MPT-AMP)) are available from bacteria ( Fig. 2c-e) . These data suggest that moc-1, moc-2, moc-3, and moc-4 mutant animals grow and develop by acquiring mature Moco from E. coli.
By contrast, moc-5 mutant C. elegans displayed little or no growth on ΔMoaA or ΔMoaC E. coli, but near wild-type growth on E. coli lacking MoaD, MoaE, or MoeB (Fig. 2a,b) . MoaD, MoaE, and MoeB mutant E. coli accumulate cPMP ( Supplementary Fig. 2b ) 15 . moc-5 mutant C. elegans is unable to make its own cPMP, but possesses all of the downstream machinery to use cPMP to synthesize mature Moco. Thus, these genetic data suggest that cPMP provided by the MoaD, MoaE, or MoeB mutant E. coli is bioavailable and supports the growth of moc-5 mutant animals deficient in the production of cPMP. MogA and MoeA mutant E. coli also synthesize cPMP. Why do they not support the growth and development of moc-5 mutant worms as well as MoaD, MoaE, and MoeB mutant E. coli (Fig. 2b) ? We speculate that cPMP does not accumulate in MogA and MoeA mutant E. coli because they possess the enzymes that convert cPMP to MPT or MPT-AMP, respectively.
What form of Moco is taken up by C. elegans from E. coli? Although animals use the di-oxo form of Moco (referred to as 'Moco' in this manuscript), the majority of E. coli molybdenum-utilizing enzymes are in the DMSO reductase family that use bis-MGD Moco. This dinucleotide Moco variant is not used by eukaryotes and requires the activity of the MobA enzyme for its synthesis in E. coli ( Supplementary Fig. 2b ) 16 . To test whether the bis-MGD form of Moco is transferred from E. coli to C. elegans, we tested the ability of moc-1 mutant C. elegans to grow on ΔMobA E. coli. moc-1 mutant animals grew normally on ΔMobA bacteria (Fig. 1c) 
, and moc-1(ok366) (f) animals were cultured from synchronized L1 larvae for 72 h on wild-type and mutant E. coli disrupted at distinct steps in Moco biosynthesis. E. coli mutations used here are nonpolar and should not disrupt other genes in their operons. Animal lengths were determined for each condition. The moc-1(ok366) mutation is a 1.4 kb deletion that is predicted to be a null allele. The moc-4(ok2571) mutation is a 1.8 kb deletion that is predicted to be a null allele. moc-2(mg595) is a nonsense mutation (G72Stop) followed by a frameshift that is a likely null allele. moc-3(ku300) is an established genetic reagent that represents a probable loss-of-function or null allele 8 . moc-5(mg589) is a missense mutation (G303R) that is a probable loss-of-function or null allele. Box plots display the median, upper, and lower quartiles, and whiskers indicate minimum and maximum data points. Sample size (n) is displayed for each experiment.
mutant C. elegans. Only when grown with supplemental molybdate do ModA or ModC mutant E. coli support the growth of moc-1 mutant C. elegans (Fig. 1c,d) . No other E. coli mutants displayed this molybdate suppression (Fig. 1d ).
An alternative explanation for the ability of wild-type E. coli to support the growth of moc-1 mutant C. elegans is that the animal imports the gene products (mRNA or protein) of the bacterial Moco-biosynthesis enzymes. To exclude this possibility, we cultured moc-1 mutant C. elegans on a 1:1 mixture of nonpolar MoaA and MoaD deletion E. coli strains. Neither of these strains individually supports the growth of moc-1 mutant animals ( Fig. 1c ), yet the dietary combination of MoaA and MoaD bacterial strains possesses all of the genes necessary for Moco biosynthesis. The MoaA + MoaD mixture caused larval arrest similar to either individual strain, suggesting that the complete set of E. coli Mocobiosynthetic mRNAs or enzymes present in the combination of the mutant bacterial strains are not transferred to complement C. elegans Moco deficiency (Fig. 1c) . Instead, our data support a model that the Moco prosthetic group and cPMP produced by E. coli cells is transferred to C. elegans.
The C. elegans MOC-1 protein is homologous to bacterial and mammalian enzymes that insert molybdenum into MPT-AMP to synthesize mature Moco. We tested if the requirement for this enzyme could also be suppressed by high levels of molybdate. Indeed, moc-1 mutant animals grown on MoaA mutant E. coli supplemented with 5 mM molybdate partially bypass the requirement for MOC-1 in the synthesis of Moco ( Supplementary Fig. 4 ).
Moco-deficient phenotypes are promoted by CTH-2 and CDO-1.
To better understand why C. elegans lacking endogenous and dietary Moco are not viable, we sought genetic suppressors of this lethality. We EMS-mutagenized populations of moc-2, moc-3, and moc-4 C. elegans mutants and grew them on wild-type E. coli until the F2 generation. We then challenged the F2 generation animals to grow on ΔMoaA E. coli, which normally causes completely penetrant larval arrest (Fig. 2) . We identified 49 independent mutant strains that grew robustly and reproduced in the absence of Moco (Supplementary Table 4 ). To determine the causative genetic lesions in these mutants, DNA from each strain was analyzed by whole-genome sequencing 18 . Based on the presence of multiple independent alleles, we identified mutations in two different genes that allow the viability of Moco-deficient C. elegans cultured on Moco-deficient E. coli. A mutation in either of these 2 genes was present in all 49 of the strains isolated in our screen.
We identified 45 alleles of the C. elegans cystathionine gammalyase, cth-2/ZK1127.10. These 45 alleles affected 37 distinct amino acid positions and included 9 nonsense and 36 missense mutations, suggesting that cth-2 loss of function suppresses the growth arrest caused by C. elegans Moco deficiency ( Fig. 3 and Supplementary Table 4 ). Cystathionine gamma-lyase, an enzyme conserved across all kingdoms of life, catabolizes cystathionine into cysteine, ammonia, and α-ketobutyrate, on the main axis of sulfur amino acid metabolism (Fig. 4a ) 6 . To demonstrate the requirement of cth-2 gene activity for the inviability of Mocodeficient C. elegans grown on Moco-deficient E. coli, we genetically transferred the cth-2(mg599) allele, predicted to cause a premature stop (W 21 Stop), into the moc-1 mutant background and assayed growth and development. Like wild-type animals, cth-2 mutant animals grew well on both wild-type and ΔMoaA E. coli. moc-1 mutant animals grew well on wild-type E. coli, but displayed early larval arrest on ΔMoaA E. coli (Fig. 3a) . cth-2; moc-1 double mutant animals grew well on both wild-type and ΔMoaA E. coli (Fig. 3a) , demonstrating that the activity of cth-2 is required for larval arrest caused by C. elegans Moco deficiency. cth-2 is one of two cystathionine gamma-lyase-encoding genes in C. elegans. The CTH-1 protein, 86% identical to CTH-2, is not redundant with CTH-2 because only cth-2 alleles emerged from this screen.
We also identified four alleles of C. elegans cysteine dioxygenase, cdo-1/F56F10.3. We identified three missense mutations affecting conserved amino acids in the cdo-1 active site and one nonsense mutation, suggesting that loss of function of cdo-1 suppresses the growth arrest caused by C. elegans Moco deficiency ( Fig. 3 and Supplementary Table 4) . Cysteine dioxygenase acts immediately downstream of CTH-2 in the sulfur amino acid metabolism pathway, catalyzing the reaction of cysteine with dioxygen to generate cysteine sulfinate (Fig. 4) 6 . To demonstrate the requirement of cdo-1 for the growth arrest of Moco-deficient C. elegans, we genetically transferred the cdo-1(mg622) allele (C85Y) into the moc-1 mutant background and assayed growth and development. cdo-1 moc-1 double mutant animals grew well on both wild-type and ΔMoaA E. coli, recapitulating the suppression identified in our screen (Fig. 3a) . In addition, cth-2 and cdo-1 mutations suppressed embryogenesis defects caused by maternal Moco deficiency (Supplementary Table 2 ).
Sulfites inhibit development during Moco deficiency.
We reasoned that CTH-2-and CDO-1-dependent catabolism of sulfur amino acids generates a product that is toxic if Moco is deficient. To test this idea, we treated animals with cysteine, a product of CTH-2 and a substrate for CDO-1, and tested for reversion of the cth-2(lf) or cdo-1(lf) suppression of Moco-deficient larval arrest on ΔMoaA E. coli (Fig. 4a) . Wild-type animals display a half-maximum inhibitory concentration (IC 50 ) of 6.0 mM cysteine. The cth-2 mutant animals display an IC 50 of 8.4 mM cysteine (Fig. 4b,c) . In contrast, cth-2; moc-1 double mutant animals are sensitive to cysteine (IC 50 of 1.0 mM cysteine); at 3 mM cysteine cth-2; moc-1 mutants arrest early in development (Fig. 4c,e) . Thus, cth-2; moc-1 double mutant animals are eight times more sensitive to cysteine than the cth-2 single mutant, demonstrating that under Moco-deficient conditions, cysteine, a CTH-2 catabolic product, promotes larval arrest. By contrast, cdo-1 and cdo-1 moc-1 mutant animals grew well on ΔMoaA E. coli at most cysteine concentrations, displaying a normal IC 50 of 5.6 mM and 4.1 mM cysteine, respectively (Fig. 4c,e ). These results demonstrate that the activity of CDO-1 is required for the larval arrest caused by supplemental cysteine during Moco deficiency. To further explore the relationship between cth-2, cdo-1, and cysteine, we analyzed the growth of cth-2; cdo-1 moc-1 triple mutant animals with cysteine. The cth-2; cdo-1 moc-1 triple mutant (IC 50 of 3.1 mM cysteine) displays growth on cysteine similar to cdo-1 moc-1 (IC 50 of 4.0 mM) double mutants and grows much better on cysteine than cth-2; moc-1 double mutants (IC 50 of 0.4 mM) (Fig. 4d,e ). These data demonstrate that the function of cdo-1 is epistatic to cth-2 and cysteine supplementation and support the model that a cysteine catabolic product downstream of CDO-1 is responsible for the larval arrest caused by Moco deficiency.
Sulfites are produced via sulfur amino acid catabolism downstream of both CTH-2 and CDO-1 (Fig. 4a) . If cysteine-derived sulfites inhibit growth and development during Moco deficiency, supplemental sulfite should cause inviability independent of the activity of CTH-2 or CDO-1 during Moco deficiency. We cultured synchronized wild-type, cth-2, cdo-1, cth-2; moc-1, and cdo-1 moc-1 mutant animals on Moco-deficient E. coli supplemented with sulfite, and analyzed growth. When supplemented with 5 mM sulfite, wild-type, cth-2, and cdo-1 mutant animals display a slight developmental delay while cth-2; moc-1 and cdo-1 moc-1 double mutant animals have arrested development or die early in development (Fig. 4f ). These data demonstrate that when animals are Moco-deficient, sulfites cause developmental arrest independent of both CTH-2 and CDO-1. We conclude that accumulation of sulfite generated by sulfur amino acid catabolism is toxic to C. elegans if animals are Moco-deficient.
The previous experiments were all performed on animals fed ΔMoaA E. coli eliminating contribution of dietary Moco. We wondered whether dietary Moco could support C. elegans growth and development when animals are challenged with supplemental cysteine or sulfite. We assayed the growth of moc-1 mutant C. elegans fed wild-type E. coli, competent for Moco synthesis, supplemented with 3 mM cysteine or 5 mM sulfite. Even when fed E. coli providing dietary Moco, moc-1 mutant animals were sensitive to supplemental cysteine and sulfite compared to wild-type animals ( Supplementary Fig. 5 ). Thus, sufficient Moco to respond to environmental challenges to sulfur homeostasis cannot be derived from dietary sources alone.
Moco-deficient defects explained by loss SUOX-1 activity. In animals, sulfite is oxidized to sulfate by the Moco-requiring enzyme, sulfite oxidase (SUOX; encoded by suox-1 in C. elegans) (Fig. 4a) . This reaction transfers electrons from sulfite to cytochrome C and the electron transport chain to generate sulfate, a proton gradient, and ATP
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. Moco is also required for the function of three other animal enzymes; xanthine oxidoreductase, aldehyde oxidase, and mitochondrial amidoxime reducing component 4 . However, because the genetic suppressors of C. elegans Moco deficiency act in a pathway that produces sulfite, the pathology of C. elegans Moco deficiency is cleanly explained by a defect in sulfite oxidation. To test this model, we characterized suox-1-null and hypomorphic mutations. We found that suox-1 is an essential gene; suox-1 null mutant animals display completely penetrant larval lethality (0% of suox-1(mg663)-null mutant animals are viable (n = 16) when grown on wild-type E. coli). Furthermore, the larval lethality of suox-1-null mutant animals is suppressed by mutations in cth-2 (90% of cth-2(mg599); suox-1(mg663) animals were viable and fertile (n = 19) when grown on wild-type E. coli). Thus, loss of suox-1 phenocopies Moco-deficient phenotypes in C. elegans.
We also characterized suox-1 missense mutations generated by the C. elegans Million Mutation Project (MMP) (Supplementary Table 5 ) 20 . One of the suox-1 alleles analyzed, suox-1(gk738847) (D391N), grew normally on wild-type E. coli, but displayed a severe developmental delay when cultured on ΔMoaA E. coli (Fig. 5a,b ) and a reduced embryo viability when adult mothers were cultivated on Moco-deficient bacteria (Supplementary Table 2 ). Similar to Moco deficiency, these phenotypes were suppressed by loss of cth-2 or cdo-1 ( Fig. 5b and Supplementary Table 2) . Thus, the activities of cth-2 and cdo-1 are necessary for the developmental defects caused by reduced SUOX-1 activity. These data suggest that SUOX-1 detoxifies the sulfite produced by sulfur amino acid catabolism. Consistent with this model, the suox-1 hypomorphic mutant is hypersensitive to cysteine or sulfite, but not sulfate (Fig. 5c-f) . The phenotypic overlap between Moco deficiency and suox-1(lf) in C. elegans supports the model that the essential function of Moco is to maintain active sulfite oxidase protein and that Moco can either be synthesized in the animal cells or provided by the microbial diet.
Tissue-specific rescue of suox-1, moc-1, and cth-2. To determine in which tissues C. elegans SUOX-1 functions, we performed tissue-specific rescue experiments. The suox-1 genomic locus was expressed under the control of the rpl-28 (all tissues), sng-1 (neurons), vha-6 (intestine), myo-3 (muscle), or col-10 (hypodermis) tissue-specific promoters and tested for ability to rescue the lethality of suox-1(mg663)-null mutant animals. Transgenes expressing suox-1 in all tissues or only in the hypodermis rescued the lethality of suox-1(mg663) animals (3 out of 3 independent transgenic lines were viable for each transgene). By contrast, expression of suox-1 in the neurons, muscle, or intestine failed to rescue the lethality of suox-1(mg663) (0 out of 3 independent transgenic lines were viable for each of these transgenes). This suggests that the hypodermis is the primary site of C. elegans sulfite detoxification.
To determine the sites of MOC-1 activity, we performed similar tissue-specific rescue experiments. The moc-1 genomic locus was expressed under the control of its native promoter, or the sng-1 (neurons), vha-6 (intestine), myo-3 (muscle), or col-10 (hypodermis) tissue-specific promoters. Multiple transgenic strains expressing moc-1 under the control of these promoters were tested for their ability to rescue the larval arrest of moc-1 mutant animals grown on ΔMoaA E. coli. Transgenes expressing moc-1 under the control of its own promoter or the hypodermis-specific promoter rescued the larval arrest phenotype of moc-1 mutant animals when grown on ΔMoaA E. coli (Fig. 6a) . The muscle-specific Pmyo-3::MOC-1 transgene caused consistent rescue, although not as complete as moc-1 driven by its own promoter or a hypodermal promoter (Fig. 6a) . moc-1 expression in neurons or the intestine did not rescue the inviability of moc-1 mutant animals grown on ΔMoaA E. coli (Fig. 6a) . These data suggest that, similar to suox-1, the primary site of Moco biosynthesis is the C. elegans hypodermis. Distinct from suox-1, C. elegans muscle also appears to be a functional site of Moco synthesis via moc-1 activity.
To determine the functional tissues of CTH-2 activity, we similarly expressed the cth-2 genomic locus under the control of its native promoter or tissue-specific promoters. Multiple transgenic strains expressing cth-2 under the control of these promoters were tested for their ability to promote larval arrest of cth-2; moc-1 mutant animals grown on ΔMoaA E. coli. Transgenic cth-2 expression by the native cth-2, the hypodermal, or the intestinal promoters displayed strong rescue activity (Fig. 6b) . cth-2 expressed in the muscle also displayed weak rescue activity while cth-2 expressed in neurons did not rescue (Fig. 6b) . These transgenes did not affect cth-2; moc-1 double mutant worms when animals were cultured on wild-type E. coli. These data suggest that CTH-2-mediated sulfur amino acid catabolism occurs in the C. elegans hypodermis, intestine, and muscle.
Discussion
The ability to synthesize Moco is conserved across all kingdoms of life and organisms have previously been thought to rely solely upon de novo synthesis to maintain Moco homeostasis. Here, we show that C. elegans imports microbial Moco and the Moco precursor cPMP from the bacteria on which it feeds. The interkingdom transfer of these metabolites raises the possibility that transport of cPMP and/or Moco between cells, tissues, and organisms may be widespread. Ancient and nearly universal enzyme cofactors such as B vitamins, heme, and enzyme cofactors such as Moco, have probably been shared between organisms for billions of years. Organisms become reliant on exogenous sources of these cofactors, often via evolutionary loss of biosynthetic pathways. For example, C. elegans and some parasitic nematodes have lost heme biosynthetic enzymes, now acquiring heme solely from dietary sources 21 . The evolutionary maintenance or loss of cofactor biosynthesis and acquisition pathways is likely to be a function of bioavailability of the cofactor and the metabolic cost of producing the cofactor de novo. For C. elegans, it appears to be beneficial to have retained both the ability to synthesize Moco as well as to acquire it from its microbial diet.
In what state is Moco transferred from E. coli to C. elegans? There is no known pool of free or stored Moco in bacterial cells and the oxygen sensitivity of the mature cofactor make it unlikely that unbound Moco is the transferred molecule. It is possible that C. elegans ingests Moco bound to the bacterial Moco-utilizing proteins or the Moco-biosynthetic enzymes, and that this proteincofactor interaction protects the cofactor during the uptake process. In this model, C. elegans would extract Moco from the E. coli proteins and incorporate it into its own Moco-requiring enzymes, such as SUOX-1. The mechanism of Moco transfer from bacteria to nematode remains to be discovered.
Could the intercellular transfer of cPMP and Moco be a conserved phenomenon? Cells from humans with Moco deficiency secrete the Moco-intermediate cPMP, which can be acquired by heterologous cells in vitro and support the synthesis of mature Moco 22 . This work laid the foundation for the idea of treating Moco deficiency with cPMP supplementation; 21 years later, a human patient with Moco deficiency was successfully treated with intravenous cPMP 23 . cPMP supplementation is only efficacious if patients possess the enzymes to convert cPMP into mature Moco. The successful treatment of human patients with Moco deficiency with cPMP parallels the ability of C. elegans to acquire cPMP from dietary E. coli, and suggest that this might be a conserved phenomenon. Furthermore, our demonstration of transfer of mature Moco from E. coli to C. elegans offers hope to deliver mature Moco, perhaps even from the microbiome, as a therapy to treat Moco deficiency in patients who are refractory to cPMP treatment.
Why is Moco essential? In addition to its role as a cofactor, some Moco-biosynthetic enzymes have additional conserved activities such as tRNA thiolation (MOCS3) and promotion of glycine receptors clustering in neurons (Gephyrin) [24] [25] [26] . Our genetic suppressors of Moco-deficient larval arrest identified mutations in cystathionine gamma-lyase (cth-2) or cysteine dioxygenase (cdo-1). These enzymes catalyze sequential steps in the catabolism of methionine and cysteine. Our pharmacological studies demonstrate that sulfite produced by these enzymes is the key toxin that causes developmental arrest during Moco deficiency. Although the exact mechanism by which sulfites are toxic to C. elegans is mysterious, sulfites are known to biochemically alter RNA, DNA, and proteins [27] [28] [29] . Sulfite also reacts with cystine to produce S-sulfocysteine (SSC), which is structurally similar to glutamate and a potent trigger of neural cell (gk738847), and cdo-1(mg622) suox-1(gk738847) animals were cultured from the first larval stage on wild-type (a) or ΔMoaA (b) E. coli. c-f, Wild-type or suox-1(gk738847) mutant animals were cultured from the first larval stage on wild-type E. coli (c), or wild-type E. coli supplemented with 3 mM cysteine (d), 5 mM sulfite (e), or 5 mM sulfate (f). Animals were cultured for 72 h and animal lengths were quantified. Box plots display the median, upper, and lower quartiles, and whiskers indicate minimum and maximum data points. Sample size (n) is displayed for each experiment. Please note, the wild-type data points displayed in c-f are also displayed in Supplementary Fig. 5 , as these assays were performed in parallel and use the same wild-type controls. death 30 . Whether these modes of toxicity contribute to the inviability of Moco-and SUOX-1-deficient C. elegans is unknown. Humans are exposed to both endogenous sulfites, via catabolism of dietary methionine and cysteine 6 , and exogenous sulfites owing to their widespread use as food preservatives 27 . These sulfites are detoxified by the Moco-requiring sulfite oxidase enzyme which oxidizes sulfite to sulfate to be excreted 31, 32 . Our suppressor mutations in cth-2 or cdo-1 block the production of sulfites that accumulate during Moco deficiency, permitting growth and development. This is a conserved phenomenon: reducing sulfite production by limiting dietary intake of methionine and cysteine yields biochemical and clinical improvements in human patients with mild sulfite oxidase deficiency 33, 34 . Thus, inhibition of cystathionine gamma-lyase or cysteine dioxygenase in human patients suffering from Moco deficiency or sulfite oxidase deficiency might further alleviate the toxicity of endogenously produced sulfites.
Our tissue-specific rescue studies of suox-1 suggest that the hypodermis is the major site of SUOX-1-mediated sulfite detoxification. We also found that the hypodermis is the major site of Moco biosynthesis (Fig. 6a) . These data suggest that Moco is both synthesized (via MOC-1) and utilized (via SUOX-1) primarily in the hypodermis. However, the muscle is also a site of MOC-1-mediated Moco biosynthesis, but is not a site of SUOX-1 activity. A possible explanation for this asymmetry of Moco synthesis and utilization is that Moco may be synthesized in muscle and transported to the hypodermis where it supports SUOX-1 activity. Intestine-specific expression of moc-1 does not rescue the moc-1 inviability when animals are grown on Moco-deficient E. coli, suggesting that the intestine is not a site of Moco biosynthesis. Given that dietary E. coli-derived Moco can support the growth and development of moc-1 mutant worms, it is likely that dietary Moco is taken up through the intestine and transported to the hypodermis to support SUOX-1 activity. Therefore, the intestine may be specialized in uptake and distribution of dietary Moco while the muscle and hypodermis may be the primary sites of endogenous Moco synthesis. Identifying the mechanisms by which endogenous and dietary Moco are transported between animal tissues will be an exciting area of future research.
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Any methods, additional references, Nature Research reporting summaries, source data, statements of data availability and associated accession codes are available at https://doi.org/10.1038/ s41589-019-0249-y. n = 9 n = 9 n = 9 n = 9 n = 6 n = 7 n = 7 n = 7 n = 7 n = 8 n = 8 n = 9 n = 9 n = 9 n = 8 N o n t r a n s g e n i c -1 and cth-2 . a, Nontransgenic moc-1(ok366) and moc-1(ok366) transgenic animals expressing moc-1 under the control of the moc-1 (native, gray), sng-1 (neurons, green), vha-6 (intestine, purple), myo-3 (muscle, orange), or col-10 (hypodermis, blue) promoters were cultured for 72 h from the first larval stage on MoaA mutant E. coli and animal lengths were quantified. Each rescue construct was tested with three independently isolated transgenes. b, Nontransgenic cth-2(mg599); moc-1(ok366) and cth-2(mg599); moc-1(ok366) transgenic animals expressing cth-2 under the control of the cth-2 (native, grey), sng-1 (neurons, green), vha-6 (intestine, purple), myo-3 (muscle, orange), or col-10 (hypodermis, blue) promoters were cultured for 72 h from the first larval stage on MoaA mutant E. coli and animal lengths were quantified. Each rescue construct was tested with two or three independently isolated transgenes. Box plots display the median, upper, and lower quartiles, and whiskers indicate minimum and maximum data points. Sample size (n) is the number of individuals assayed and is displayed for each experiment.
Methods
Caenorhabditis elegans. C. elegans strains were cultured at 20 °C on NGM seeded with E. coli OP50 unless otherwise noted 35 . The wild-type strain was Bristol N2. All C. elegans strains used in this work, their developmental stage at time of experiment, culture conditions, outcrossing status, and their sources are listed in Supplementary Table 3 or in the figure legends.
Bacteria. The wild-type bacterial strains were E. coli (OP50) or E. coli (K-12), as indicated in the figure legends and Methods section. All bacterial strains used in this work, their culture conditions, and their sources are listed in Supplementary  Table 3 or the figure legends.
Plasmid construction and transgenesis. All plasmids used in this manuscript are listed in Supplementary Table 3. All cloning was performed using isothermal (Gibson) assembly in a pBluescript plasmid backbone 36 . Tissue-specific rescue plasmids were constructed by amplifying the suox-1, moc-1, and cth-2 genomic loci from wild-type C. elegans genomic DNA. Each locus was amplified from the start codon to the stop codon, including all exons and introns, and inserted into plasmids that encoded the appropriate tissue-specific promoter and carboxyterminal green fluorescent protein. Transgenic animals carrying extrachromosomal arrays were generated by injecting the gonad of worms with a plasmid of interest and a co-injection marker 37 . The co-injection marker was Pmyo-2::mCherry for all strains analyzed in this manuscript, except for GR2258, which utilized a Pmyo-3::GFP co-injection marker 38 . All transgenic C. elegans strains are listed in Supplementary Table 3. C. elegans growth assays. C. elegans were synchronized at the first stage of larval development (L1). L1 animals were then cultured on NGM seeded with wild-type or mutant E. coli K-12. The strains of E. coli used are noted specifically for each assay and are listed in Supplementary Table 3. For cysteine, sulfite, or sulfate sensitivity assays, NGM was seeded with wildtype or ΔMoaA E. coli K-12 and then supplemented with various concentrations of L-cysteine (0, 0.00062, 0.0012, 0.0031, 0.0062, and 0.12 M), sodium metabisulfite (0.005 M), or sodium sulfate (0.005 M). Synchronized L1 animals were placed onto the various cysteine, sulfite, or sulfate culture conditions and were allowed to develop for 48 or 72 h (specified in figure legends) at 20 °C.
For all assays, after the growth period was completed live animals were imaged using an Axio Zoom.V16 microscope (Zeiss) equipped with an ORCA-Flash4.0 digital camera (Hamamatsu). Images were captured using ZEN software (Zeiss) and processed utilizing ImageJ (Version 2). Animal length was measured from the tip of the head to the end of the tail. The concentration of supplemental cysteine that caused 50% of the wild-type growth (IC 50 ) was calculated with nonlinear regression analyses using GraphPad Prism software (version 8).
Quantification of embryo hatching rate. To determine the hatching rate of wildtype and mutant C. elegans when cultured under various growth conditions, we performed synchronized egg lays using young adults. Embryos were then scored for hatching 12-24 h after being laid. To facilitate adult-specific Moco deficiency, in some experiments L4 animals were shifted onto either wild-type or ΔMoaA E. coli, allowed to develop to the young adult stage and their progeny were assayed for their ability to hatch.
Screening for E. coli gene activities required for the growth and development of C. elegans lacking endogenous Moco biosynthesis. To identify E. coli gene activities that are required for the growth of moc-1(ok366) animals, we utilized the Keio collection of deletion E. coli strains (NIG). Each of the approximately 4,000 deletion strains are derived from the E. coli K-12 strain BW25113 (ref. 12 ). Each strain was cultured overnight in LB with 50 μg ml -1 kanamycin. Of this 2 ml overnight culture, 0.1 ml was seeded on NGM and allowed to dry and grow overnight at room temperature (~22-23 °C), creating a lawn of bacteria.
Concurrently, approximately 200,000 moc-1(ok366) animals grown on E. coli OP50, which is wild-type for Moco biosynthetic pathway genes, were prepared with sodium hypochlorite to generate eggs and sterilize the E. coli from the parental feeding. These eggs were then allowed to hatch overnight without food and were synchronized at the L1 stage. 30-50 L1 animals were dispersed onto each unique deletion strain of E. coli. These animals were cultured for 2 d at room temperature (~22-23 °C). Wells were then scored for growth. Here we report deletion strains of E. coli that caused early larval growth arrest of moc-1(ok366) animals.
To more cleanly analyze the E. coli strains identified in our screen, we used established methods to remove the kanamycin resistance cassette from each Keio strain of interest 12 . This process results in the deletion of the E. coli gene of interest and leaves behind a sequence that codes for a 34 amino acid peptide. Importantly, this peptide coding sequence is in frame, allowing downstream genes in that operon to be functional. Thus, these deletions are nonpolar and allowed genetic interpretation of the single gene knockout. Nonpolar mutant strains were used in Figs. 1c,d, 2, and Supplementary Fig. 3 . All other strains still contained the kanamycin resistance cassette and might be polar, thus affecting the entire operon of interest.
Identification of F49E2.1/moc-5 and W01A11.6/moc-2 as genes required for growth during dietary Moco deficiency. To define C. elegans gene activities that were required for growth during dietary Moco deficiency, we carried out a chemical mutagenesis screen for animals that were unable to grow and develop on ΔMoaA E. coli. Wild-type C. elegans were mutagenized with ethyl methanesulfonate (EMS) and grown on wild-type E. coli for two generations. We then screened for mutant animals in the F2 generation that failed to develop when cultured on ΔMoaA E. coli but grew well on wild-type E. coli 35 . We isolated two mutant alleles in this screen, mg589 and mg639.
Using whole-genome sequencing and linkage analyses we determined that mg589 was located on the X linkage group and identified five candidate lesions on linkage group X that might be the mg589 mutation. Candidate lesions were homozygous and were predicted to alter the protein sequence. One of these five candidates, F49E2.1, is homologous to E. coli MoaA and MoaC, genes with established roles in Moco biosynthesis. F49E2.1 has a long isoform F49E2.1b and a short isoform F49E2.1a, both of which are predicted to use the same start codon. The lesion in F49E2.1 changes a Gga glycine codon to an Aga encoding an arginine. This missense mutation results in a G303R change in the encoded peptide. Interestingly, glycine 303 is conserved in E. coli MoaA, C. elegans F49E2.1, and human MOCS1, suggesting its functional importance. Glycine 303 is present in both isoforms of F49E2.1.
Our linkage, sequencing, and homology data strongly suggested F49E2.1 was the gene affected by mg589. To independently demonstrate this, we rescued mg589-mutant animals with the F49E2.1 wild-type genomic locus. To generate the rescuing plasmid, we engineered pBluescript to contain the entire wild-type F49E2.1 locus from 1,502 base pairs upstream of the ATG start codon to 722 base pairs downstream of the F49E2.1b stop codon. Thus, the rescuing plasmid (pKW20, F49E2.1(+), also known as Pmoc-5::MOC-5) contained the endogenous promoter, exons, introns, and untranslated regions of both F49E2.1a and F49E2.1b, and no other genes.
Transgenic animals containing extrachromosomal arrays were generated by injecting the gonad of mg589-mutant worms with pKW20 and a Pmyo-3::GFP co-injection marker 37, 38 . Pmyo-3::GFP is a plasmid with the myo-3 promoter driving the expression of green fluorescent protein in the body wall muscles. Transgenic strains were selected and maintained based on the heritable transmission of GFP in the body wall muscle. We isolated four independently derived transgenic mg589 strains expressing F49E2.1(+).
To test the ability of F49E2.1 to rescue the mg589 phenotype, we cultured mg589+F49E2.1(+) animals and their nontransgenic siblings on ΔMoaA E. coli. For all four transgenic strains isolated, the transgenic mg589+F49E2.1(+) animals grew and developed well on ΔMoaA E. coli while the nontransgenic sibling mg589 animals did not. These results demonstrate that the F49E2.1 genetic locus rescued the mg589 growth defect during dietary Moco deficiency. Thus, based on linkage, sequencing, homology, and rescue data, we conclude that F49E2.1 is the gene affected by the mg589 mutation. We rename F49E2.1 as moc-5 for molybdenum cofactor biosynthesis.
Using whole-genome sequencing and linkage analyses we determined that mg639 was located on linkage group V and identified eight candidate lesions on linkage group V that might be the mg639 mutation. Candidate lesions were homozygous and were predicted to alter the protein sequence. One of these eight candidates, moc-2, is homologous to E. coli MogA, a gene with an established role in Moco biosynthesis. The lesion in moc-2 changes a gCa alanine codon to a gTa encoding a valine. This missense mutation results in an A136V change in the encoded peptide.
Our linkage, sequencing, and homology data strongly suggested moc-2 was the gene affected by mg639. However, the sensitivity of animals carrying the mg639 mutation to growth on ΔMoaA E. coli was not as dramatic as other mutations in C. elegans Moco biosynthetic enzymes ( Supplementary Fig. 6 and Supplementary Table 2 ). Furthermore, A136V is likely to be a subtle loss of function, as alanine and valine are very similar amino acids. Therefore, we speculated that mg639 might be a hypomorphic allele of moc-2. To test this hypothesis and independently demonstrate that moc-2 was the gene affected by mg639, we generated a presumptive null mutation in moc-2 using CRISPR-Cas9 technology 9 .
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Data collection
Live animals were imaged using an Axio Zoom.V16 microscope (Zeiss) equipped with an ORCA-Flash4.0 digital camera (Hamamatsu). Images were captured using ZEN software (Zeiss) and processed utilizing ImageJ.
Data analysis
The concentration of supplemental cysteine that caused 50% of the wild-type growth (IC50) was calculated with nonlinear regression analyses using GraphPad Prism software (Version 8). Sequencing data was analyzed using publicly available CloudMap (https:// usegalaxy.org/u/gm2123/p/cloudmap).
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